ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...

Adults who reported 2 to less than 3 hours of weekend catch-up sleep had a significantly lower prevalence of CKD compared with those reporting less than 1 hour of WCS (AOR, 0.44; 95% CI, 0.21-0.88).

Preventive health check-ups in 2026 are essential for early disease detection and long-term well-being. Experts recommend ...

ASN Kidney Week, held in November, featured leading-edge science in kidney care, with evidence supporting new drugs to treat ...

Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.

Algorithms in clinical decision tools have been making it harder for certain racial and socioeconomic groups to receive the healthcare they deserve.

The updated guideline addresses rapid advances in pharmacologic management, balancing use of newer, older drugs.

Medically reviewed by David Ozeri, MD IgA nephropathy can be diagnosed with a combination of a physical exam, symptom assessment, medical history review, and special tests.The tests that can confirm ...

Biomarkers associated with cognitive impairment differ between men and women with chronic kidney disease, according to data ...

Medically reviewed by Jamin Brahmbhatt, MD Key Takeaways Complement 3 glomerulopathy (C3G) is diagnosed with a combination of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Recommendations include use of ACE-I or ARB to slow CKD progression in patients with hypertension and albuminuria.